|Ms. Susan B. Washer||Pres, CEO & Director||777.27k||N/A||1961|
|Dr. Mark S. Shearman||Chief Scientific Officer||538.93k||N/A||1960|
|Dr. Matthew Feinsod||Exec. VP of Global Strategy & Devel.||711.2k||N/A||1971|
|Dr. Nicholas Muzyczka||Co-Founder||N/A||N/A||N/A|
|Dr. Barry J. Byrne||Co-Founder||N/A||N/A||N/A|
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. It focuses in the field of ophthalmology, with clinical programs in X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), and achromatopsia (ACHM), as well as a preclinical program in optogenetics. The company also has initiated preclinical programs in adrenoleukodystrophy and otology indications. Applied Genetic Technologies Corporation has collaboration agreements with Synpromics Limited; Bionic Sight, LLC; and Otonomy, Inc. The company was founded in 1999 and is headquartered in Alachua, Florida.
Applied Genetic Technologies Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.